GPC2 and neoplasm: Among these are a second-generation CAR-T targeting the signaling co-receptor glypican-2 (GPC2) and a second-generation CAR-T targeting B7-H3, both well-known tumor antigens expressed by multiple pediatric cancers, including neuroblastoma [5], [6].